Avoro Capital Advisors’s Tango Therapeutics TNGX Stock Holding History

Avoro Capital Advisors’s Portfolio TNGX Stock Details TNGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-545,000	Closed	-$4.58M	–	42
2025 Q3	$4.58M	Buy	+545,000	New	+$3.69M	0.06%	30
2023 Q4	–	Sell	-2,222,222	Closed	-$25M	–	49
2023 Q3	$25M	Buy	2,222,222 +582,222	+36%	+$3.55M	0.39%	30
2023 Q2	$5.44M	Hold	1,640,000	–	–	0.07%	40
2023 Q1	$6.48M	Hold	1,640,000	–	–	0.1%	37
2022 Q4	$11.9M	Buy	1,640,000 +90,000	+6%	+$633K	0.18%	34
2022 Q3	$5.61M	Hold	1,550,000	–	–	0.1%	37
2022 Q2	$7.02M	Hold	1,550,000	–	–	0.14%	36
2022 Q1	$11.7M	Hold	1,550,000	–	–	0.21%	37
2021 Q4	$17M	Hold	1,550,000	–	–	0.29%	34
2021 Q3	$20M	Buy	1,550,000 +750,000	+94%	+$8.99M	0.31%	39
2021 Q2	$9.1M	Hold	800,000	–	–	0.16%	42
2021 Q1	$8.9M	Hold	800,000	–	–	0.15%	44
2020 Q4	$9.15M	Hold	800,000	–	–	0.16%	41
2020 Q3	$8.67M	Buy	+800,000	New	+$8.17M	0.12%	44

Other funds holding TNGX

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Avoro Capital Advisors's TNGX Position: Q4 2025 in Review

Avoro Capital Advisors sold out of Tango Therapeutics (TNGX) in Q4 2025, closing a stake of 545,000 shares — an estimated $4.58M sold.

Avoro Capital Advisors first reported a position in TNGX in Q3 2020 and held it in 14 quarters. The position peaked at $25M in Q3 2023. 170 funds tracked by Wall St. Rank hold TNGX as of Q4 2025.

Avoro Capital Advisors reported no remaining Tango Therapeutics position as of Q4 2025 after selling out during the quarter.
Avoro Capital Advisors sold 545,000 Tango Therapeutics shares in Q4 2025, an estimated $4.58M.
Avoro Capital Advisors first reported a position in Tango Therapeutics in Q3 2020 and held it in 14 quarters.
Avoro Capital Advisors's Tango Therapeutics position peaked at $25M in Q3 2023.
170 funds tracked by Wall St. Rank held Tango Therapeutics as of Q4 2025.

Based on Avoro Capital Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.